These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 15613980

  • 1. Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice.
    Delsing DJ, Post SM, Groenendijk M, Solaas K, van der Boom H, van Duyvenvoorde W, de Wit EC, Bloks VW, Kuipers F, Havekes LM, Princen HM.
    J Cardiovasc Pharmacol; 2005 Jan; 45(1):53-60. PubMed ID: 15613980
    [Abstract] [Full Text] [Related]

  • 2. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background impairs very-low-density lipoprotein production.
    Post SM, Groenendijk M, Solaas K, Rensen PC, Princen HM.
    Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):768-74. PubMed ID: 14962946
    [Abstract] [Full Text] [Related]

  • 3. Cafestol increases serum cholesterol levels in apolipoprotein E*3-Leiden transgenic mice by suppression of bile acid synthesis.
    Post SM, de Roos B, Vermeulen M, Afman L, Jong MC, Dahlmans VE, Havekes LM, Stellaard F, Katan MB, Princen HM.
    Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1551-6. PubMed ID: 10845871
    [Abstract] [Full Text] [Related]

  • 4. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs.
    van Vlijmen BJ, Pearce NJ, Bergö M, Staels B, Yates JW, Gribble AD, Bond BC, Hofker MH, Havekes LM, Groot PH.
    Arzneimittelforschung; 1998 Apr; 48(4):396-402. PubMed ID: 9608883
    [Abstract] [Full Text] [Related]

  • 5. Dietary plant stanol esters reduce VLDL cholesterol secretion and bile saturation in apolipoprotein E*3-Leiden transgenic mice.
    Volger OL, van der Boom H, de Wit EC, van Duyvenvoorde W, Hornstra G, Plat J, Havekes LM, Mensink RP, Princen HM.
    Arterioscler Thromb Vasc Biol; 2001 Jun; 21(6):1046-52. PubMed ID: 11397718
    [Abstract] [Full Text] [Related]

  • 6. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin.
    Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ, Kooistra T, Havekes LM.
    Circulation; 2003 Sep 16; 108(11):1368-74. PubMed ID: 12939225
    [Abstract] [Full Text] [Related]

  • 7. Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia.
    Chong T, Naples M, Federico L, Taylor D, Smith GJ, Cheung RC, Adeli K.
    Atherosclerosis; 2006 Mar 16; 185(1):21-31. PubMed ID: 16002078
    [Abstract] [Full Text] [Related]

  • 8. Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats.
    Okada Y, Yamaguchi K, Nakajima T, Nishikawa T, Jo M, Mitsumoto Y, Kimura H, Nishimura T, Tochiki N, Yasui K, Mitsuyoshi H, Minami M, Kagawa K, Okanoue T, Itoh Y.
    Liver Int; 2013 Feb 16; 33(2):301-11. PubMed ID: 23295058
    [Abstract] [Full Text] [Related]

  • 9. Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet.
    Shimizu T, Miura S, Tanigawa H, Kuwano T, Zhang B, Uehara Y, Saku K.
    Arterioscler Thromb Vasc Biol; 2014 Oct 16; 34(10):2246-53. PubMed ID: 25104799
    [Abstract] [Full Text] [Related]

  • 10. Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/- mice exposed to a high cholesterol diet.
    Famer D, Crisby M.
    Neurosci Lett; 2007 May 23; 419(1):68-73. PubMed ID: 17433542
    [Abstract] [Full Text] [Related]

  • 11. Effects of dietary fish oil on serum lipids and VLDL kinetics in hyperlipidemic apolipoprotein E*3-Leiden transgenic mice.
    van Vlijmen BJ, Mensink RP, van 't Hof HB, Offermans RF, Hofker MH, Havekes LM.
    J Lipid Res; 1998 Jun 23; 39(6):1181-8. PubMed ID: 9643349
    [Abstract] [Full Text] [Related]

  • 12. Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis.
    Huang Y, Ji ZS, Brecht WJ, Rall SC, Taylor JM, Mahley RW.
    Arterioscler Thromb Vasc Biol; 1999 Dec 23; 19(12):2952-9. PubMed ID: 10591675
    [Abstract] [Full Text] [Related]

  • 13. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis.
    Chen J, Li D, Schaefer RF, Mehta JL.
    J Cardiovasc Pharmacol; 2004 Oct 23; 44(4):446-52. PubMed ID: 15454852
    [Abstract] [Full Text] [Related]

  • 14. Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells.
    Qin S, Koga T, Ganji SH, Kamanna VS, Kashyap ML.
    Metabolism; 2008 Jul 23; 57(7):973-9. PubMed ID: 18555840
    [Abstract] [Full Text] [Related]

  • 15. Upregulation of hepatic LDL receptor-related protein in nephrotic syndrome: response to statin therapy.
    Kim S, Kim CH, Vaziri ND.
    Am J Physiol Endocrinol Metab; 2005 Apr 23; 288(4):E813-7. PubMed ID: 15585592
    [Abstract] [Full Text] [Related]

  • 16. CETP expression enhances liver HDL-cholesteryl ester uptake but does not alter VLDL and biliary lipid secretion.
    Harada LM, Amigo L, Cazita PM, Salerno AG, Rigotti AA, Quintão EC, Oliveira HC.
    Atherosclerosis; 2007 Apr 23; 191(2):313-8. PubMed ID: 16806230
    [Abstract] [Full Text] [Related]

  • 17. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver.
    Mensenkamp AR, Jong MC, van Goor H, van Luyn MJ, Bloks V, Havinga R, Voshol PJ, Hofker MH, van Dijk KW, Havekes LM, Kuipers F.
    J Biol Chem; 1999 Dec 10; 274(50):35711-8. PubMed ID: 10585451
    [Abstract] [Full Text] [Related]

  • 18. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
    Krause BR, Newton RS.
    Atherosclerosis; 1995 Oct 10; 117(2):237-44. PubMed ID: 8801869
    [Abstract] [Full Text] [Related]

  • 19. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1.
    Jong MC, Dahlmans VE, van Gorp PJ, Breuer ML, Mol MJ, van der Zee A, Frants RR, Hofker MH, Havekes LM.
    Arterioscler Thromb Vasc Biol; 1996 Aug 10; 16(8):934-40. PubMed ID: 8696956
    [Abstract] [Full Text] [Related]

  • 20. Dietary sphingolipids lower plasma cholesterol and triacylglycerol and prevent liver steatosis in APOE*3Leiden mice.
    Duivenvoorden I, Voshol PJ, Rensen PC, van Duyvenvoorde W, Romijn JA, Emeis JJ, Havekes LM, Nieuwenhuizen WF.
    Am J Clin Nutr; 2006 Aug 10; 84(2):312-21. PubMed ID: 16895877
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.